Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Rhea-AI Summary

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) will participate in two investor conferences. The first is the Guggenheim 4th Annual Immunology and Neurology Day on November 14, 2022, in New York, NY. The second is the J.P. Morgan Equity Opportunities Forum on November 15, 2022, in Miami, FL. A live webcast of Acadia's presentation at the Guggenheim conference will be available at www.acadia.com at 9:35 a.m. Eastern Time.

Acadia focuses on neuroscience breakthroughs, including therapies for Parkinson’s disease psychosis and negative symptoms of schizophrenia.

SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences:

Guggenheim 4^th Annual Immunology and Neurology Day
November 14, 2022 in New York, NY

J.P. Morgan Equity Opportunities Forum
November 15, 2022 in Miami, FL

A live webcast of Acadia’s presentation at the Guggenheim conference at 9:35 a.m. Eastern Time on November 14, 2022 will be accessible on the company’s website, www.acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation.

About Acadia Pharmaceuticals

Acadia is advancing breakthroughs in neuroscience to elevate life. For more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson’s disease psychosis. Our clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Rett syndrome and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia.com and follow us on LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221108006174/en/

Media Contact:

Acadia Pharmaceuticals Inc.

Deb Kazenelson

(818) 395-3043

media@acadia-pharm.com

Investor Contact:

Acadia Pharmaceuticals Inc.

Mark Johnson, CFA

(858) 261-2771

ir@acadia-pharm.com

 

Source: Acadia Pharmaceuticals Inc.

FAQ

When is Acadia Pharmaceuticals' participation at the Guggenheim conference?

Acadia Pharmaceuticals will participate in the Guggenheim 4th Annual Immunology and Neurology Day on November 14, 2022.

Where is the J.P. Morgan Equity Opportunities Forum being held?

The J.P. Morgan Equity Opportunities Forum will be held in Miami, FL on November 15, 2022.

What time will Acadia Pharmaceuticals present at the Guggenheim conference?

Acadia Pharmaceuticals' presentation at the Guggenheim conference will start at 9:35 a.m. Eastern Time.

How can I access Acadia Pharmaceuticals' live webcast?

The live webcast of Acadia's presentation can be accessed on their website at www.acadia.com.

What therapeutic areas does Acadia Pharmaceuticals focus on?

Acadia Pharmaceuticals focuses on treatments for Parkinson’s disease psychosis, schizophrenia, and neuropsychiatric symptoms in CNS disorders.